immunoglobulin domain


Also found in: Wikipedia.

immunoglobulin domain

[‚im·yə·nō‚gläb·yə·lən də′mān]
(immunology)
The basic structural unit of immunoglobulins.
References in periodicals archive ?
ALPN-101 is a novel Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD), and a first-in-class therapeutic simultaneously inhibiting the CD28 and ICOS inflammation pathways.
Piper Jaffray analyst Edward Tenthoff notes that Alpine Immune Sciences presented two posters at SITC for immuno-oncology variable Immunoglobulin Domain candidates.
The extracellular region of TIM-3 consists of a mucin domain and an immunoglobulin domain to which the known ligands of TIM-3 bond, that is, galectin-9 (Gal-9) and phosphatidylserine (Ps) [48, 49].
Briefly, The templates used for modeling of immunoglobulin domain (pdb ID:2C5D), fibronectin type 3 domain (pdb ID:4PBX) and protein tyrosine kinase domain (pdb ID:3QUP) was found from RCSB protein data bank [21] based on high sequences homology and designed individually.
Molecular structure of these proteins is similar to that of immunoglobulins having a domain known as an immunoglobulin domain or fold.
Granzier, "Single molecule force spectroscopy on titin implicates immunoglobulin domain stability as a cardiac disease mechanism," The Journal of Biological Chemistry, vol.
The extracellular part of Ror proteins contains an immunoglobulin domain, a cysteine rich domain, also called a frizzled domain and a kringle domain (3-7).
Jovine's team solved the structure of a mouse ZP-N region and found that the type of fold in the ZP-N is a twist on a protein shape called the immunoglobulin domain, which is well-known for its presence in antibodies.
(NASDAQ: ALPN) has released results of a preclinical study of novel immuno-oncology molecules derived from the company's variant immunoglobulin domain platform, the company said.
More detailed information of their function and associated pathways will serve to clarify their relationship to vertebrate immunoglobulin domain receptors.
(NASDAQ: ALPN) has released results from preclinical studies evaluating ALPN-101 program dual ICOS/CD28 antagonists generated by the company's variant immunoglobulin domain platform, the company said.
Full browser ?